The Pattern Repeats
Scandal erupts. Villains are identified and punished. Everyone celebrates the system working as intended.
But that's only half the story.
The other half is what the system was doing before the collapse. What structural conditions made the outcome nearly unavoidable. Why the same structures keep appearing in different industries, different eras, and different organizations while we keep reaching for the same human explanations.
The Pattern Repeats doesn't exonerate the actors. The damage was real and the accountability was earned. It asks the harder question. What made this rational when it should have been unthinkable. And what does that tell us about where it's happening right now. The case studies are simplified to focus on the structure, the consequences are not.
Blood Money
This edition: when the bridge becomes the only way forward.
You have an idea that seems genius.
You can simplify the process of medical care for millions in the US and expand in depth care options to those in countries without sophisticated medical infrastructure. You can see it all clearly. But seeing it clearly and bringing it into reality are two very different things. It's going to cost hundreds of millions of dollars.
You've already taken on millions in investor funding and, next week, you're supposed to present your current progress.
One problem.
The work is progressing slower than you expected. You still feel you're on the right track and you're just a single breakthrough away from everything working. But you also know if you tell your investors that, today, you have nothing actionable to show them, the funding will dry up almost overnight and the future will never come.
You realize something in that moment. You can create a demonstration that makes it look like the technology is further along than it actually is. Investors are happy, you get another year of funding to make the breakthrough, everyone wins.
Do you build the demo?
In January 2003, a nineteen-year-old Stanford dropout incorporated a company called Real-Time Cures. She would later rename it Theranos, a portmanteau of therapy and diagnosis. The vision was genuine and the ambition was staggering: a device that could run hundreds of diagnostic tests from a single finger-prick of blood, delivering results in minutes rather than days, at a fraction of the cost of traditional lab work.
The technology did not exist. But Elizabeth Holmes believed it would.
That distinction matters more than almost anything else written about this case.
What the lifestyle tells us
The dominant Theranos narrative is a straightforward fraud story. A sociopathic founder fabricated results, deceived investors, endangered patients, and escaped accountability for years behind a wall of NDAs and litigation threats. The villain is clearly identified. The moral is obvious.
But fraud narratives require a motive and the most common one is personal enrichment. Here the story starts to fracture.
Holmes did not live lavishly. There was no yacht. No compound. No conspicuous accumulation of personal wealth that you would expect from someone running a nine-figure extraction operation. The capital that flowed into Theranos flowed back into Theranos. Into the Palo Alto headquarters, the partnerships, the board, the apparatus of the company itself.
We cannot know her motivations with certainty and we will not assign them here. But the lifestyle is data. Someone purely extracting value eventually extracts it. Holmes kept building the bridge. None of this excludes ego, status, or self-delusion as motivators. But it complicates the theory that Theranos existed primarily as a cash extraction vehicle that the founders knew had no promise.
If lifestyle doesn't support the argument for extraction being the true motivation, we have to look to a different variable.
The mechanism the money created
Here is a counterfactual worth sitting with. If Elizabeth Holmes had pursued the same research through government grants rather than venture capital, the story may have ended differently.
Grant funding operates on a different accountability structure. Milestones are scientific rather than commercial. Peer review tolerates failure as information. A promising technology that needs another decade of development is fundable in that world. You do not need to show investors a product that works. You need to show a scientific community that your methodology is sound.
This is not to say that government grants are the inherently superior funding mechanism. Only that different capital sources carry different structural pressures, and those pressures shape behavior before any individual decision is made.
Venture capital required something else entirely. It required a story that justified the valuation. It required proof points that demonstrated momentum. It required, in a field as complex and slow-moving as medical diagnostics, results that the science was not yet capable of producing.
The first small exaggeration probably didn't feel like fraud. It felt like a temporary bridge; a necessary simplification to secure the capital that would make the simplification true. The endpoint was real in her mind. The bridge was a means to it.
That is how the hope bridge begins.
The hope bridge
Every founder who has ever been six months from bankruptcy and six months from breakthrough understands the arithmetic of the hope bridge.
The technology needs more time. The money runs out before the time does. The investor needs to believe the technology is closer than it is. You tell them it is closer than it is. You use their money to try to make it true. You tell yourself that when you get there (and you will get there), the temporary nature of the bridge will be obvious to everyone. The harm will be forgiven in the light of what you built.
The bridge becomes load-bearing. The exaggerations compound because each round of funding requires a more compelling story than the last. The gap between what exists and what is claimed widens. The structure now requires maintaining the bridge above all else because the bridge is the only thing keeping the research alive.
And somewhere in that cycle, the bridge stops being a means to the destination and becomes the destination itself. Keeping it standing is all that matters.
This is not unique to Elizabeth Holmes. This is what the structure produces.
The collapse
The Theranos bridge collapsed for reasons that were partly scientific, partly structural, and ultimately human. The technology never closed the gap. Real patients received real test results from machines that could not produce reliable data. At some point the bridge was no longer serving a future breakthrough. It was serving the bridge.
That is where the structure stops being an explanation and becomes something else. The hope bridge does not absolve the harm caused to patients who made medical decisions based on false results. It does not explain the decision to keep it standing when the destination was no longer visible. It explains the conditions that made the bridge rational to build.
The bridges that held
Amazon lost money for years. Investors were told to believe in a future that did not yet exist and to trust that the infrastructure being built would eventually justify the losses. They were right.
Tesla was perpetually on the edge of insolvency for the better part of a decade. The bridge between what existed and what Musk promised was long and expensive and required its own cycle of belief maintenance. It held.
SpaceX nearly ran out of money before the first successful Falcon 1 launch. Three failures before the fourth flight saved the company. The bridge held by months.
The structural conditions in each of these cases were not different from Theranos. A founder. A vision that outpaced current capability. Investor capital filling the gap between present reality and future promise. A bridge built on belief rather than proof.
The difference was not the character of the founder. The difference was whether the destination existed.
Amazon's retail infrastructure stabilized. The electric vehicle scaled. The rocket reached orbit. The finger-prick blood panel that could run 200 tests with existing technology couldn't find a working mechanism in time.
The bridge is the same structure in every case. What sits at the end of it determines whether history calls it vision or fraud.
In innovation, victory often hides sins that failure exposes.